IVIEW Therapeutics
iVIEW Therapeutics Inc. is a clinical-stage ophthalmology-focused therapeutics company based in Cranbury, New Jersey. The company is committed to the treatment of ocular diseases with high unmet medical needs through innovative small molecule drugs and gene therapy approaches. Their focus on novel mechanisms of action and proprietary drug delivery technology platforms allows them to develop highly differentiated assets with potentially superior target product profiles. Their portfolio includes products for Acute Infectious Conjunctivitis, Dry Eye Disease, Myopia, and Glaucoma.
Industries
Nr. of Employees
small (1-50)
IVIEW Therapeutics
Products
Ophthalmic eyelid wipe for dry eye (IND-cleared)
Topical eyelid-wipe formulation developed to treat signs and symptoms of dry eye disease; cleared for clinical investigation via IND by FDA.
Therapeutic candidate for fungal keratitis (FDA orphan designation)
Ophthalmic therapeutic candidate addressing fungal keratitis that has received orphan drug designation from the U.S. FDA.
Pipeline candidates for acute infectious conjunctivitis, dry eye, myopia and glaucoma
Portfolio of development-stage ophthalmic candidates addressing multiple indications including acute infectious conjunctivitis, dry eye disease, myopia and glaucoma.
Ophthalmic eyelid wipe for dry eye (IND-cleared)
Topical eyelid-wipe formulation developed to treat signs and symptoms of dry eye disease; cleared for clinical investigation via IND by FDA.
Therapeutic candidate for fungal keratitis (FDA orphan designation)
Ophthalmic therapeutic candidate addressing fungal keratitis that has received orphan drug designation from the U.S. FDA.
Pipeline candidates for acute infectious conjunctivitis, dry eye, myopia and glaucoma
Portfolio of development-stage ophthalmic candidates addressing multiple indications including acute infectious conjunctivitis, dry eye disease, myopia and glaucoma.
Services
Scientific presentations and forum participation
Presenting ophthalmic research at scientific meetings and participating in industry roundtables and forums to disseminate data and engage collaborators.
Collaborative research and development partnerships
Engagement in external collaborations for preclinical and clinical development of ophthalmic therapeutics and delivery platforms.
Scientific presentations and forum participation
Presenting ophthalmic research at scientific meetings and participating in industry roundtables and forums to disseminate data and engage collaborators.
Collaborative research and development partnerships
Engagement in external collaborations for preclinical and clinical development of ophthalmic therapeutics and delivery platforms.
Expertise Areas
- Clinical trial management for ophthalmology
- Regulatory strategy and FDA interactions (IND, orphan designation)
- Ocular gene therapy development
- Small-molecule discovery for eye diseases
Key Technologies
- Ocular gene therapy
- TRPM8 ion-channel modulation
- Target-based small-molecule discovery
- In-situ gelling ophthalmic formulations